Thyroid News and Research

RSS

Study reveals dangerous chemicals in foam carpet pads

In the first public study of its kind, a type of foam carpet pad commonly sold in the USA was demonstrated to contain flame retardant chemicals that raise concerns about human health. Lowered IQ's in children exposed in utero, infertility, and cancer are among health effects linked to exposure from these halogenated chemicals.

29 Apr 2011

Health effects of Chernobyl nuclear crisis remain unknown 25 years after incident

Though it has been 25 years since a disastrous explosion at the Chernobyl nuclear power plant in Ukraine sent radioactive material into the air, affecting Russia, Ukraine and Belarus, as well as the rest of the world, "experts are still debating the long-term health effects of the disaster," the Los Angeles Times' "Booster Shots" blog reports.

28 Apr 2011

Alkem, Karo Bio partner to license eprotirome

Karo Bio has entered into a collaboration and license agreement with the Indian pharmaceutical company Alkem Laboratories Ltd.

26 Apr 2011

AstraZeneca selects Biologics as U.S. channel partner for vandetanib

Biologics, Inc., an integrated oncology management company, is pleased to announce it has been selected by AstraZeneca as the exclusive U.S. strategic channel partner for vandetanib.

25 Apr 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Worm protein controls key aspects of secretion of growth factors out of cells

Research in the worm is shedding light on a protein associated with a number of different human cancers, and may point to a highly targeted way to treat them.

22 Apr 2011

Fleming ramps up production of ThyroShield to meet increased domestic and international demand

Fleming Pharmaceuticals, maker of ThyroShield– the only FDA approved liquid potassium iodide product indicated for thyroid protection in radiation emergencies – announced today that it has implemented the changes necessary to ramp up production to meet increased domestic and international demand.

22 Apr 2011

Also in global health news: Nuclear accidents; measles outbreak in Europe; funding shortfall in Zimbabwe; drinking water in Pakistan; agricultural development in S. Asia

The world must prepare for more major nuclear accidents, U.N. Secretary-General Ban Ki-moon said on Wednesday at a Kiev conference marking the explosion of a reactor at Ukraine's Chernobyl nuclear reactor 25 years ago, the Associated Press reports.

22 Apr 2011

Proteins could lead to new therapeutic target for NF2: Wistar Institute researchers

The proteins that provide cells with a sense of personal space could lead to a therapeutic target for Neurofibromatosis Type 2, an inherited cancer disorder, according to researchers at The Wistar Institute. Their findings, which appear in the April 12 issue of the journal Cancer Cell, could have profound implications for NF2 and related cancers, such as mesothelioma.

16 Apr 2011

Organic pollutants in flame retardents cause molecular changes in reproductive organs

Polybrominated diphenyl ethers (PBDEs) are chemicals that have been widely used as flame retardants and are now classified as persistent organic pollutants. Health concerns in humans have arisen based primarily on studies with laboratory animals exposed to high levels of PBDEs. Three commercial mixtures of PBDEs have been manufactured in or imported into the United States which include penta-, octa-, and deca-brominated diphenyl ethers (BDEs).

15 Apr 2011

Study finds minimally invasive thyroid surgery effective in pediatric patients

Surgical approaches that reduce incision size and recovery time from thyroid surgery work well in children, physician-scientists report.

15 Apr 2011

New research suggests iodine-deficiency in large UK population

New research suggests the UK population is now iodine-deficient and a full review and evidence-based recommendations are needed to safeguard public health.

12 Apr 2011

Research on rare cancers

A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, "Where should I be treated?" Patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer.

11 Apr 2011

New ATA recommendations on outpatient 131I therapy aim to treat thyroid cancer

New recommendations from the American Thyroid Association on outpatient radioiodine treatment aim to minimize unintended radiation exposure and maximize the safety of patients, their families, and the public.

8 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

MEDX announces first installations of next generation T-Quest compact gamma camera

MEDX, Inc., a leading provider of nuclear medicine equipment, today introduced the next generation T-Quest™ compact gamma camera. The FDA-cleared T-Quest, includes enhanced thyroid imaging and now features expanded imaging capabilities to perform parathyroid, sentinel node, MUGA, gastric emptying, hepatobiliary, bone spots and other small organ studies.

6 Apr 2011

Asuragen launches InformThyroid, a panel of molecular markers

Asuragen, Inc. announced today the launch of Inform™Thyroid, a panel of molecular markers used on Fine Needle Aspirates (FNA) of thyroid nodules to aid physicians in the management of thyroid cancer.

6 Apr 2011

Thyroid News and Research

Study reveals dangerous chemicals in foam carpet pads

Health effects of Chernobyl nuclear crisis remain unknown 25 years after incident

Alkem, Karo Bio partner to license eprotirome

AstraZeneca selects Biologics as U.S. channel partner for vandetanib

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

Worm protein controls key aspects of secretion of growth factors out of cells

Fleming ramps up production of ThyroShield to meet increased domestic and international demand

Also in global health news: Nuclear accidents; measles outbreak in Europe; funding shortfall in Zimbabwe; drinking water in Pakistan; agricultural development in S. Asia

Proteins could lead to new therapeutic target for NF2: Wistar Institute researchers

Organic pollutants in flame retardents cause molecular changes in reproductive organs

Study finds minimally invasive thyroid surgery effective in pediatric patients

New research suggests iodine-deficiency in large UK population

Research on rare cancers

New ATA recommendations on outpatient 131I therapy aim to treat thyroid cancer

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

MEDX announces first installations of next generation T-Quest compact gamma camera

Asuragen launches InformThyroid, a panel of molecular markers

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News